直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

IPR and CBM Statistics for Final Written Decisions Issued in March 2016

April 28, 2016

Authored and Edited by David C. Seastrunk; Elliot C. Cook; Daniel F. Klodowski; Aaron L. Parker

In the 63 Final Written Decisions issued by the Patent Trial and Appeal Board in March, the Board cancelled 559 (65.00%) of the instituted claims and declined to cancel 251 (29.19%) of the instituted claims. Patent owners conceded 50 (5.81%) of the instituted claims through motions to amend or disclaimer. These numbers are considerably better for patentees than the February 2016 numbers, where 79.45% of all instituted claims were cancelled and only 18.12% of instituted claims survived.

PTAB-STATS-Claim-and-Case-Disposition-IPR-Claim-March-Stats

On a per-case basis, no instituted or substitute claims survived in 42 (66.67%) of the decisions, all instituted claims survived in 18 (28.57%) of the decisions, and a mixed outcome occurred in 3 (4.76%) of the decisions. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision. These numbers are also significantly more favorable to patentees than the February 2016 numbers, where no instituted claims survived in 82.86% of cases and all instituted claims survived in only 5.71% of cases.

PTAB-STATS-Claim-and-Case-Disposition-IPR-Case-March-Stats

The following resources are also available on the AIA Blog:

  • More detailed cumulative statistics on the Board’s IPR and CBM decisions, updated through April 1, 2016
  • Lists of the top 10 PTAB judges by panel appearances and authored opinions
  • Numbers of final written decisions by technology center

Various other PTAB metrics collected and generated by Finnegan are reserved for the use of Finnegan and its clients.

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Contacts

Elliot C. Cook
Partner
Reston, VA
+1 571 203 2738
Email
Daniel F. Klodowski
Partner
Washington, DC
+1 202 408 4216
Email
Aaron L. Parker
Partner
Washington, DC
+1 202 408 4387
Email

Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP